Valerie S Honndorf1, Holger Schmidt2, Stefan Wiehr1, Hans F Wehrl1, Leticia Quintanilla-Martinez3, Anke Stahlschmidt1, Hervé Barjat4, Sally-Ann Emmas4, Bernd J Pichler5. 1. Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University, Tübingen, Germany. 2. Department of Radiology, Diagnostic and Interventional Radiology, Eberhard Karls University, Tübingen, Germany. 3. Institute for Pathology, Eberhard Karls University, Tübingen, Germany. 4. Personalized Healthcare and Biomarkers, AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK. 5. Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University, Tübingen, Germany. Bernd.Pichler@med.uni-tuebingen.de.
Abstract
PURPOSE: Positron emission tomography (PET) and diffusion-weighted MRI (DW-MRI) were used to characterize the treatment effects of the MEK1/2 inhibitor selumetinib (AZD6244), docetaxel, and their combination in HCT116 tumor-bearing mice on the molecular level. PROCEDURES: Mice were treated with vehicle, selumetinib (25 mg/kg), docetaxel (15 mg/kg), or a combination of both drugs for 7 days and imaged at four time points with 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) or 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) followed by DW-MRI to calculate the apparent diffusion coefficient (ADC). Data was cross-validated using the Pearson correlation coefficient (PCC) and compared to histology (IHC). RESULTS: Each drug led to tumor growth inhibition but their combination resulted in regression. Separate analysis of PET or ADC could not provide significant differences between groups. Only PCC combined with IHC analysis revealed the highest therapeutic impact for combination therapy. CONCLUSION: Combination treatment of selumetinib/docetaxel was superior to the respective mono-therapies shown by PCC of PET and ADC in conjunction with histology.
PURPOSE: Positron emission tomography (PET) and diffusion-weighted MRI (DW-MRI) were used to characterize the treatment effects of the MEK1/2 inhibitor selumetinib (AZD6244), docetaxel, and their combination in HCT116 tumor-bearing mice on the molecular level. PROCEDURES: Mice were treated with vehicle, selumetinib (25 mg/kg), docetaxel (15 mg/kg), or a combination of both drugs for 7 days and imaged at four time points with 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) or 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) followed by DW-MRI to calculate the apparent diffusion coefficient (ADC). Data was cross-validated using the Pearson correlation coefficient (PCC) and compared to histology (IHC). RESULTS: Each drug led to tumor growth inhibition but their combination resulted in regression. Separate analysis of PET or ADC could not provide significant differences between groups. Only PCC combined with IHC analysis revealed the highest therapeutic impact for combination therapy. CONCLUSION: Combination treatment of selumetinib/docetaxel was superior to the respective mono-therapies shown by PCC of PET and ADC in conjunction with histology.
Authors: Julia G Mannheim; Martin S Judenhofer; Andreas Schmid; Julia Tillmanns; Detlef Stiller; Vesna Sossi; Bernd J Pichler Journal: Phys Med Biol Date: 2012-05-31 Impact factor: 3.609
Authors: Tammie C Yeh; Vivienne Marsh; Bryan A Bernat; Josh Ballard; Heidi Colwell; Ron J Evans; Janet Parry; Darin Smith; Barbara J Brandhuber; Stefan Gross; Allison Marlow; Brian Hurley; Joe Lyssikatos; Patrice A Lee; James D Winkler; Kevin Koch; Eli Wallace Journal: Clin Cancer Res Date: 2007-03-01 Impact factor: 12.531
Authors: Pasi A Jänne; Alice T Shaw; José Rodrigues Pereira; Gaëlle Jeannin; Johan Vansteenkiste; Carlos Barrios; Fabio Andre Franke; Lynda Grinsted; Victoria Zazulina; Paul Smith; Ian Smith; Lucio Crinò Journal: Lancet Oncol Date: 2012-11-28 Impact factor: 41.316
Authors: S V Holt; A Logié; R Odedra; A Heier; S P Heaton; D Alferez; B R Davies; R W Wilkinson; P D Smith Journal: Br J Cancer Date: 2012-02-16 Impact factor: 7.640
Authors: Natalie J Serkova; Kristine Glunde; Chad R Haney; Mohammed Farhoud; Alexandra De Lille; Elizabeth F Redente; Dmitri Simberg; David C Westerly; Lynn Griffin; Ralph P Mason Journal: Cancer Res Date: 2020-12-01 Impact factor: 13.312
Authors: Sonja Schelhaas; Kathrin Heinzmann; Vikram R Bollineni; Gerbrand M Kramer; Yan Liu; John C Waterton; Eric O Aboagye; Anthony F Shields; Dmitry Soloviev; Andreas H Jacobs Journal: Theranostics Date: 2017-01-01 Impact factor: 11.556
Authors: Sonja Schelhaas; Lynn Johann Frohwein; Lydia Wachsmuth; Sven Hermann; Cornelius Faber; Klaus P Schäfers; Andreas H Jacobs Journal: Mol Imaging Biol Date: 2021-11-09 Impact factor: 3.484